These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12063634)

  • 1. Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT.
    Zatelli MC; Tagliati F; Taylor JE; Piccin D; Culler MD; degli Uberti EC
    Horm Metab Res; 2002 May; 34(5):229-33. PubMed ID: 12063634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt.
    Zatelli MC; Tagliati F; Taylor JE; Rossi R; Culler MD; degli Uberti EC
    J Clin Endocrinol Metab; 2001 May; 86(5):2161-9. PubMed ID: 11344221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.
    Zatelli MC; Tagliati F; Piccin D; Taylor JE; Culler MD; Bondanelli M; degli Uberti EC
    Biochem Biophys Res Commun; 2002 Oct; 297(4):828-34. PubMed ID: 12359227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro.
    Tagliati F; Zatelli MC; Bottoni A; Piccin D; Luchin A; Culler MD; Degli Uberti EC
    Endocrinology; 2006 Jul; 147(7):3530-8. PubMed ID: 16601140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
    Tulipano G; Bonfanti C; Milani G; Billeci B; Bollati A; Cozzi R; Maira G; Murphy WA; Poiesi C; Turazzi S; Giustina A
    Neuroendocrinology; 2001 May; 73(5):344-51. PubMed ID: 11399907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro.
    Zatelli MC; Piccin D; Bondanelli M; Tagliati F; De Carlo E; Culler MD; Uberti EC
    Horm Metab Res; 2003 Jun; 35(6):349-54. PubMed ID: 12920656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT.
    Bläker M; Arrenberg P; Stange I; Schulz M; Burghardt S; Michaelis H; Pace A; Greten H; von Schrenck T; de Weerth A
    Regul Pept; 2004 Apr; 118(1-2):111-7. PubMed ID: 14759564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cortistatin-14 inhibits cell proliferation of human thyroid carcinoma cell lines of both follicular and parafollicular origin.
    Cassoni P; Muccioli G; Marrocco T; Volante M; Allia E; Ghigo E; Deghenghi R; Papotti M
    J Endocrinol Invest; 2002 Apr; 25(4):362-8. PubMed ID: 12030609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Bottoni A; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Taylor JE; Culler MD; Cavazzini L; degli Uberti EC
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5181-8. PubMed ID: 15472224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid.
    Zatelli MC; Maffei P; Piccin D; Martini C; Rea F; Rubello D; Margutti A; Culler MD; Sicolo N; degli Uberti EC
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2104-9. PubMed ID: 15671091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcitonin receptor mRNA expression in TT cells: effect of dexamethasone.
    Frendo JL; Delage-Mourroux R; Cohen R; Pichaud F; Pidoux E; Guliana JM; Jullienne A
    Mol Cell Endocrinol; 1998 Apr; 139(1-2):37-43. PubMed ID: 9705072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The intratumoral immunoassayable somatostatin concentration is frequently elevated in medullary thyroid carcinoma. Results in 34 cases.
    Modigliani E; Alamowitch C; Cohen R; Calmettes C; Guliana JM; Franc B; Bernard C; Chayvialle JA
    Cancer; 1990 Jan; 65(2):224-8. PubMed ID: 1967221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines.
    Ain KB; Taylor KD; Tofiq S; Venkataraman G
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1857-62. PubMed ID: 9177396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
    Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
    J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
    Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
    J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptors: from basic science to clinical approach--thyroid.
    Zatelli MC; degli Uberti EC
    Dig Liver Dis; 2004 Feb; 36 Suppl 1():S86-92. PubMed ID: 15077916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of octreotide on expression of calcitonin gene in cultured cells of medullary thyroid carcinoma.
    Zabel M
    Histol Histopathol; 2004 Jul; 19(3):793-7. PubMed ID: 15168342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers.
    Carmona Matos DM; Jang S; Hijaz B; Chang AW; Lloyd RV; Chen H; Jaskula-Sztul R
    Surgery; 2019 Jan; 165(1):64-68. PubMed ID: 30415874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.